Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumorigenicity testing: past concerns, future problems.

P D Noguchi1

  • 1Division of Biochemistry and Biophysics, Center for Biologics Evaluation and Research, Bethesda, MD 20892.

Developments in Biological Standardization
|January 1, 1992
PubMed
Summary

Tumorigenicity testing is crucial for cell substrates. New technologies require updated or novel models for assessing tumor formation potential, especially for cell therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.

Journal of immunology (Baltimore, Md. : 1950)·1996
Same author

From Jim to gene and beyond: an odyssey of biologics regulation.

Food and drug law journal·1996
Same author

Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.

The Journal of biological chemistry·1995
Same author

Xenotransplantation and xenogeneic infections.

The New England journal of medicine·1995
Same author

Cell transplantation and Federal regulation.

Cell transplantation·1995
Same author

Regulatory review of cellular and gene therapies: an overview of the process.

Transfusion science·1994

Area of Science:

  • Biotechnology and Biomedical Sciences
  • Cell Biology and Genetics
  • Regulatory Science

Background:

  • Tumorigenicity testing is a standard for characterizing cell substrates used in biopharmaceutical production.
  • Advancements in recombinant technology and cell culture have created new cell substrates.
  • Existing tumorigenicity testing models, primarily developed for vaccine production, may require adaptation.

Purpose of the Study:

  • To review current models of tumorigenicity in light of recent scientific advancements.
  • To evaluate the applicability and necessity of tumorigenicity testing for emerging fields.
  • To discuss the future of tumorigenicity assessment in cell-based therapies.

Main Methods:

  • Literature review of existing tumorigenicity models.
  • Analysis of current knowledge and technological capabilities.
  • Discussion of regulatory considerations for novel cell-based applications.

Main Results:

  • Current tumorigenicity models may not fully address the complexities of new cell substrates.
  • Recombinant technologies necessitate a re-evaluation of established testing protocols.
  • Somatic cell therapy presents unique challenges for traditional tumorigenicity assessments.

Conclusions:

  • Established tumorigenicity testing paradigms require modification due to technological progress.
  • Novel approaches to tumorigenicity assessment are needed for advanced cell therapies.
  • The field must develop new principles to ensure the safety of novel cell-based products.

Related Experiment Videos